Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Kerala Ayurveda's Revenue for the
three
months ended in Jun. 2026 was ₹332 Mil. Kerala Ayurveda's average Accounts Receivable for the
three
months ended in Jun. 2026 was ₹138 Mil.
Hence, Kerala Ayurveda's Receivables Turnover for the
three
months ended in Jun. 2026 was 2.40.
Kerala Ayurveda (BOM:530163) Receivables Turnover Explanation
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Kerala Ayurveda Receivables Turnover Related Terms
Kerala Ayurveda Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Kerala Ayurveda's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:530163 vs ZTS: Receivables Turnover Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Kerala Ayurveda's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kerala Ayurveda Receivables Turnover vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Kerala Ayurveda's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Kerala Ayurveda's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kerala Ayurveda (BOM:530163) has a Receivables Turnover of 2.40 as of Jun. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Kerala Ayurveda and its competitors. According to the industry distribution chart, Kerala Ayurveda ranks #208 out of 946 companies in the Drug Manufacturers industry, placing it in the top 22%.
Is Kerala Ayurveda's Receivables Turnover too high?
Kerala Ayurveda's current Receivables Turnover is 2.40. The Drug Manufacturers industry median Receivables Turnover is 5.10. Kerala Ayurveda's value of 2.40 is 52.9% below this industry median. Based on the distribution chart, Kerala Ayurveda ranks #208 out of 946 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Kerala Ayurveda has a GF Score™ of 48/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Kerala Ayurveda's Receivables Turnover compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Kerala Ayurveda ranks #208 out of 946 companies for Receivables Turnover. This places Kerala Ayurveda in the top 22% of its industry — outperforming the majority of peers. The industry median Receivables Turnover is 5.10. Kerala Ayurveda's value of 2.40 is 52.9% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Drug Manufacturers company?
The median Receivables Turnover among Drug Manufacturers companies is 5.10, based on 946 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Kerala Ayurveda's current Receivables Turnover of 2.40 is 52.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Kerala Ayurveda and its competitors. For the Drug Manufacturers industry, the median Receivables Turnover is 5.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kerala Ayurveda's current Receivables Turnover is 2.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kerala Ayurveda stock overvalued right now?
Based on GuruFocus' analysis, Kerala Ayurveda (BOM:530163) is currently considered Possible Value Trap. The stock's GF Value™ is ₹351.72, compared to a current price of ₹198.95 — trading 43.4% below its estimated fair value. The current Receivables Turnover is 2.40 and 52.9% below the Drug Manufacturers industry median of 5.10. Kerala Ayurveda's overall GF Score™ is 48/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Kerala Ayurveda (BOM:530163), the current Receivables Turnover is 2.40 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Kerala Ayurveda (BOM:530163) Overvalued in 2026?
Based on GuruFocus' analysis, Kerala Ayurveda stock appears to be undervalued.
The current stock price of ₹198.95 is trading 43.4% below its estimated GF Value™ of ₹351.72.
GuruFocus considers Kerala Ayurveda to be Possible Value Trap.
Key valuation signals for BOM:530163:
Receivables Turnover: 2.40
GF Value™: ₹351.72 vs. price of ₹198.95 (43.4% below fair value)
Industry Position: 52.9% below the Drug Manufacturers median (#208 of 946)
No single metric tells the full story. See the BOM:530163 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Kerala Ayurveda Ltd is engaged in producing and selling ayurvedic products and providing healthcare services. The company offers ayurvedic medicine products for diabetes and heart health, skin and hair care, kids' health, women's care, men's care, gastro care, respiratory and allergy, general healthcare, massage oils, renal care, and joint care. It provides services through wellness clinics, resorts, hospitals, and academies. The company has only one reportable business segment, i.e., Full-spectrum Ayurvedic wellness. It generates maximum revenue from the sale of products. Geographically, the company generates maximum revenue from its business in India and also has some exposure to other markets.
48GF Score
Get the complete analysis for BOM:530163
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:530163 has been successfully added to your 
